Brief Title
Comparison of Beta-blocker Versus Angiotensin Receptor Blocker for Suppression of Aneurysm Expansion in Patients With Small Abdominal Aortic Aneurysm and Hypertension (BASE Trial)
Brief Summary
Various medical therapies have been proposed to prevent abdominal aortic aneurysm expansion. However, there have been very few randomized clinical trials to support use of any of these treatments. Several animal studies and observational reports suggest that ARBs can be useful in reducing abdominal aortic aneurysm (AAA) growth. However, so far, ARBs have not been evaluated in a randomized clinical trial. Therefore, the purpose of the study is to evaluate the effect of valsartan, an ARB, on annual growth rate in comparison with atenolol, a beta-blocker. Our hypothesis is that valsartan is superior to atenolol in the suppression of the aneurysm growth at 12 months. The BASE trial is designed as a investigator-initiated, multi-center, randomized controlled open-label trial. Patients with small AAA (aorta diameter <5cm) will be randomized 1:1 either to valsartan or to atenolol group. Randomization will be stratified by the AAA size (max. diameter >4 cm or ≤4 cm). Patients will receive either valsartan (daily dose 80 mg or more) or atenolol (daily dose 50 mg or more) for 12 months. A CT scan will measure the maximal diameter of AAA at baseline and 12 months. The annual growth of AAA will be compared between the valsartan and the atenolol group.
Study Phase
Phase 4
Study Type
Interventional
Primary Outcome
Annual aneurysm growth of abdominal aortic aneurysm
Condition
Small Abdominal Aortic Aneurysm
Intervention
Beta-blocker-Atenolol 50mg, PO(peroral), Once daily
Study Arms / Comparison Groups
Atenolol
Description: Atenolol group
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Recruitment Status
Drug
Estimated Enrollment
19
Start Date
January 2014
Completion Date
April 18, 2017
Primary Completion Date
April 18, 2017
Eligibility Criteria
Inclusion Criteria: - Age ≥20years - Abdominal aortic aneurysm with maximal diameter less than 5cm - Hypertension - Patient with signed informed consent Exclusion Criteria: - Saccular type aneurysm, inflammatory aneurysm, or infected aneurysm - Aortic dissection - Planned surgery or endovascular therapy for abdominal aortic aneurysm within 1 year - Previous aorta surgery or endovascular therapy - Contraindications to Beta-blocker or ARB (allergic reactions, asthma, severe bradycardia, angioedema, hyperkalemia) - Allergic reaction to contrast dye - Known genetic aorta disease or autoimmune or connective tissue disease: Marfan syndrome, Shprintzen-Goldberg syndrome, Loeys-Dietz syndrome, Takayasu's arteritis, Behcet's disease - Pregnancy - Life expectation <1 year - Renal failure (serum Cr >2.0 mg/dL) - Liver disease (ALT or AST > 3 x upper limit) or liver cirrhosis (Child B or C) - Malignancy requiring surgery or chemotherapy within 1 year after enrollment - Status post transplantation or chronic inflammatory disease requiring immune suppressive drugs over 4 weeks
Gender
All
Ages
20 Years - 90 Years
Accepts Healthy Volunteers
No
Contacts
, ,
Location Countries
Korea, Republic of
Location Countries
Korea, Republic of
Administrative Informations
NCT ID
NCT01904981
Organization ID
4-2012-0843
Responsible Party
Sponsor
Study Sponsor
Yonsei University
Study Sponsor
, ,
Verification Date
December 2018